Related Experiment Video

Updated: Dec 9, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

508

The role of autophagy in targeted therapy for acute myeloid leukemia

Wenxin Du1, Aixiao Xu1, Yunpeng Huang1

  • 1Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Autophagy
|September 12, 2020
PubMed

Insights

Autophagy plays a key role in acute myeloid leukemia (AML) development and treatment response. Modulating autophagy offers a promising strategy for targeted AML therapy, especially given resistance to current treatments.

Area of Science:

  • Oncology
  • Cellular Biology
  • Molecular Medicine

Background:

  • Molecular targeted therapies show promise in acute myeloid leukemia (AML), but limited response and acquired resistance are significant challenges.
  • Autophagy, a cellular degradation process, is increasingly recognized for its involvement in cancer development and response to therapy, including AML.

Purpose of the Study:

  • To review the role of autophagy in the development of acute myeloid leukemia (AML).
  • To summarize the connection between autophagy and common genetic abnormalities in AML.
  • To highlight the potential of targeting autophagy for novel AML therapies.

Main Methods:

  • Comprehensive literature review of studies on autophagy in AML.
  • Analysis of the relationship between autophagy and recurrent genetic mutations in AML.
  • Evaluation of autophagy modulation as a therapeutic strategy for AML.

Main Results:

  • Autophagy is implicated in both the initiation and progression of AML.
  • Specific genetic alterations in AML are linked to dysregulated autophagy pathways.
  • Targeting autophagy may overcome resistance mechanisms in AML.

Conclusions:

  • Autophagy is a critical factor in AML pathogenesis and treatment.
  • Understanding the interplay between genetic abnormalities and autophagy is key for developing effective therapies.
  • Autophagy modulation represents a promising avenue for improving targeted therapy outcomes in AML.
Keywords:
Acute myeloid leukemiaautophagyautophagy modulatorgenetic abnormalitiesmolecular targeted therapy

More Related Videos

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry11:39

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry

Published on: July 21, 2017

31.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.6K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.8K